Perrigo Company Public Limited Company (PRGO)

$27.08

-0.07

(-0.26%)▲

Market is closed - opens 8 PM, 22 Nov 2024

Performance

  • $26.70
    $27.34
    $27.08
    downward going graph

    1.4%

    Downside

    Day's Volatility :2.34%

    Upside

    0.95%

    downward going graph
  • $23.89
    $34.60
    $27.08
    downward going graph

    11.76%

    Downside

    52 Weeks Volatility :30.94%

    Upside

    21.73%

    downward going graph

Returns

PeriodPerrigo Company Public Limited CompanySector (Health Care)Index (Russel 2000)
3 Months
-3.77%
-6.9%
0.0%
6 Months
-7.67%
-1.7%
0.0%
1 Year
-11.07%
10.4%
0.0%
3 Years
-31.01%
8.8%
-24.1%

Highlights

Market Capitalization
3.7B
Book Value
$33.45
Dividend Share
1.101
Dividend Yield
4.07%
Earnings Per Share (EPS)
-1.07
PEG Ratio
1.02
Wall Street Target Price
35.8
Profit Margin
-3.63%
Operating Margin TTM
10.44%
Return On Assets TTM
1.37%
Return On Equity TTM
-3.16%
Revenue TTM
4.4B
Revenue Per Share TTM
32.09
Quarterly Revenue Growth YOY
-3.2%
Gross Profit TTM
1.5B
EBITDA
571.9M
Diluted Eps TTM
-1.07
Quarterly Earnings Growth YOY
-0.64
EPS Estimate Current Year
2.59
EPS Estimate Next Year
3.12
EPS Estimate Current Quarter
0.81
EPS Estimate Next Quarter
0.92

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Perrigo Company Public Limited Company(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 32.2%

Current $27.08
Target $35.80

Company Financials

FY18Y/Y Change
Revenue
4.7B
↓ 4.34%
Net Income
131.0M
↑ 9.53%
Net Profit Margin
2.77%
↑ 0.35%
FY19Y/Y Change
Revenue
4.8B
↑ 2.23%
Net Income
146.1M
↑ 11.53%
Net Profit Margin
3.02%
↑ 0.25%
FY20Y/Y Change
Revenue
5.1B
↑ 4.67%
Net Income
-162.6M
↓ 211.29%
Net Profit Margin
-3.21%
↓ 6.23%
FY21Y/Y Change
Revenue
4.1B
↓ 18.26%
Net Income
-130.9M
↓ 19.5%
Net Profit Margin
-3.16%
↑ 0.05%
FY22Y/Y Change
Revenue
4.5B
↑ 7.56%
Net Income
-130.9M
↑ 0.0%
Net Profit Margin
-2.94%
↑ 0.22%
FY23Y/Y Change
Revenue
4.7B
↑ 4.58%
Net Income
-12.7M
↓ 90.3%
Net Profit Margin
-0.27%
↑ 2.67%
Q2 FY23Q/Q Change
Revenue
1.2B
↑ 0.96%
Net Income
8.4M
↓ 863.64%
Net Profit Margin
0.7%
↑ 0.79%
Q3 FY23Q/Q Change
Revenue
1.1B
↓ 5.81%
Net Income
14.2M
↑ 69.05%
Net Profit Margin
1.26%
↑ 0.56%
Q4 FY23Q/Q Change
Revenue
1.2B
↑ 2.95%
Net Income
-32.3M
↓ 327.46%
Net Profit Margin
-2.79%
↓ 4.05%
Q1 FY24Q/Q Change
Revenue
1.1B
↓ 6.45%
Net Income
4.1M
↓ 112.69%
Net Profit Margin
0.38%
↑ 3.17%
Q2 FY24Q/Q Change
Revenue
1.1B
↓ 1.53%
Net Income
-105.7M
↓ 2678.05%
Net Profit Margin
-9.92%
↓ 10.3%
Q3 FY24Q/Q Change
Revenue
1.1B
↑ 2.05%
Net Income
-21.0M
↓ 80.13%
Net Profit Margin
-1.93%
↑ 7.99%
FY18Y/Y Change
Total Assets
11.0B
↓ 5.55%
Total Liabilities
5.3B
↓ 2.62%
FY19Y/Y Change
Total Assets
11.3B
↑ 2.9%
Total Liabilities
5.5B
↑ 3.42%
FY20Y/Y Change
Total Assets
11.5B
↑ 1.65%
Total Liabilities
5.8B
↑ 6.11%
FY21Y/Y Change
Total Assets
10.4B
↓ 9.25%
Total Liabilities
5.3B
↓ 9.59%
FY22Y/Y Change
Total Assets
11.0B
↑ 5.67%
Total Liabilities
6.2B
↑ 17.09%
FY23Y/Y Change
Total Assets
10.8B
↓ 1.89%
Total Liabilities
6.0B
↓ 2.17%
Q2 FY23Q/Q Change
Total Assets
11.0B
↑ 0.09%
Total Liabilities
6.1B
↓ 0.08%
Q3 FY23Q/Q Change
Total Assets
10.8B
↓ 1.88%
Total Liabilities
6.0B
↓ 1.57%
Q4 FY23Q/Q Change
Total Assets
10.8B
↑ 0.47%
Total Liabilities
6.0B
↑ 0.35%
Q1 FY24Q/Q Change
Total Assets
10.6B
↓ 1.56%
Total Liabilities
6.0B
↓ 1.46%
Q2 FY24Q/Q Change
Total Assets
10.4B
↓ 2.28%
Total Liabilities
5.9B
↓ 1.7%
Q3 FY24Q/Q Change
Total Assets
11.2B
↑ 7.75%
Total Liabilities
6.6B
↑ 13.42%
FY18Y/Y Change
Operating Cash Flow
593.0M
↓ 15.15%
Investing Cash Flow
-126.8M
↓ 105.42%
Financing Cash Flow
-571.9M
↓ 80.97%
FY19Y/Y Change
Operating Cash Flow
387.8M
↓ 34.6%
Investing Cash Flow
-596.1M
↑ 370.11%
Financing Cash Flow
1.8M
↓ 100.31%
FY20Y/Y Change
Operating Cash Flow
636.2M
↑ 64.05%
Investing Cash Flow
-187.8M
↓ 68.5%
Financing Cash Flow
-181.1M
↓ 10161.11%
FY21Y/Y Change
Operating Cash Flow
156.3M
↓ 75.43%
Investing Cash Flow
1.3B
↓ 779.34%
Financing Cash Flow
-178.7M
↓ 1.33%
FY22Y/Y Change
Operating Cash Flow
307.3M
↑ 96.61%
Investing Cash Flow
-2.0B
↓ 253.52%
Financing Cash Flow
421.6M
↓ 335.93%
Q2 FY23Q/Q Change
Operating Cash Flow
52.9M
↑ 172.68%
Investing Cash Flow
-4.4M
↓ 77.55%
Financing Cash Flow
-48.6M
↓ 4.14%
Q3 FY23Q/Q Change
Operating Cash Flow
124.5M
↑ 135.35%
Investing Cash Flow
-30.7M
↑ 597.73%
Financing Cash Flow
-43.3M
↓ 10.91%

Technicals Summary

Sell

Neutral

Buy

Perrigo Company Public Limited Company is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Perrigo Company Public Limited Company
Perrigo Company Public Limited Company
4.88%
-7.67%
-11.07%
-31.01%
-44.75%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
7.04%
-10.35%
12.63%
45.35%
9.32%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-3.63%
12.35%
14.51%
28.88%
28.88%
Zoetis Inc.
Zoetis Inc.
-6.75%
2.71%
-1.47%
-21.23%
47.49%
Viatris Inc.
Viatris Inc.
13.54%
21.84%
41.41%
0.99%
-18.91%
Catalent, Inc.
Catalent, Inc.
-0.43%
8.53%
50.66%
-53.63%
14.64%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Perrigo Company Public Limited Company
Perrigo Company Public Limited Company
2818.0
NA
1.02
2.59
-0.03
0.01
0.04
33.45
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
33.33
33.33
0.29
6.54
0.16
0.12
NA
26.87
Haleon Plc Spon Ads
Haleon Plc Spon Ads
27.88
27.88
1.69
0.34
0.07
0.04
0.02
1.82
Zoetis Inc.
Zoetis Inc.
33.0
33.0
2.46
5.87
0.47
0.15
0.01
11.59
Viatris Inc.
Viatris Inc.
224.4
NA
0.08
2.67
-0.04
0.02
0.04
16.58
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.95
0.2
-0.11
0.0
NA
19.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Perrigo Company Public Limited Company
Perrigo Company Public Limited Company
Buy
$3.7B
-44.75%
2818.0
-3.63%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$12.7B
9.32%
33.33
17.21%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$42.9B
28.88%
27.88
10.75%
Zoetis Inc.
Zoetis Inc.
Buy
$79.2B
47.49%
33.0
26.55%
Viatris Inc.
Viatris Inc.
Hold
$15.1B
-18.91%
224.4
-5.87%
Catalent, Inc.
Catalent, Inc.
Hold
$10.7B
14.64%
211.02
-9.34%

Insights on Perrigo Company Public Limited Company

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 1.06B → 1.08B (in $), with an average increase of 2.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -105.7M → -21.0M (in $), with an average increase of 403.3% per quarter

  • Vs CTLT

    In the last 1 year, Catalent, Inc. has given 50.7% return, outperforming this stock by 61.8%

Institutional Holdings

  • Vanguard Group Inc

    10.91%

  • BlackRock Inc

    9.51%

  • Dimensional Fund Advisors, Inc.

    5.10%

  • State Street Corp

    5.01%

  • DePrince Race & Zollo Inc

    2.84%

  • Cooke & Bieler LP

    2.52%

Corporate Announcements

  • Perrigo Company Public Limited Company Dividends March,2024

    In the quarter ending March,2024. Perrigo Company Public Limited Company has declared dividend of $0.28

    Read More

Company Information

perrigo company plc, a top five global over-the-counter (otc) consumer goods and pharmaceutical company, offers consumers and customers high quality products at affordable prices. from its beginnings in 1887 as a packager of generic home remedies, perrigo, headquartered in ireland, has grown to become the world's largest manufacturer of otc products and supplier of infant formulas for the store brand market. the company is also a leading provider of branded otc products, generic extended topical prescription products and receives royalties from multiple sclerosis drug tysabri®. perrigo provides “quality affordable healthcare products®” across a wide variety of product categories and geographies primarily in north america, europe, and australia, as well as other key markets including israel and china. visit perrigo online at (http://www.perrigo.com).

Organization
Perrigo Company Public Limited Company
Employees
9140
CEO
Mr. Patrick Lockwood-Taylor
Industry
Health Technology

FAQs